Neurology

Excerpt:
The FDA has granted approval to Novartis for Itvisma (onasemnogene abeparvovec-brve), the first gene replacement therapy for spinal muscular atrophy (SMA) available for patients aged 2 years and older. Backed by data from the Phase 3 STEER and Phase 3b STRENGTH trials, this one-time intrathecal treatment addresses the genetic root cause of SMA and is expected to be available in the U.S. this December.

Metabolic syndrome raises Parkinson’s risk by 39%, especially with genetic predisposition.

🧠 + 🦠 = 🔥 Mental health matters in IBD.
Psychiatric disorders are *common* among patients with inflammatory bowel disease—up to **57%** affected.
The gut and brain are deeply connected.
#IBD #MentalHealth #GutBrainAxis @sunilmadhavs.world

🧠 A major study shows the MIND diet may cut Alzheimer’s risk by up to 25%, with greatest benefit seen in those improving diet over time. Results vary by ethnicity, highlighting need for culturally adapted plans. #BrainHealth #MINDdiet

World Brain Day (July 22) champions brain health for all. For patients & providers, the focus is on 5 keys: Awareness, Education, Prevention, Access & Advocacy. Let’s use tech, share stories & build healthy habits to protect our brains.